Sie O G, Lakke J P
Clin Neurol Neurosurg. 1980;82(4):273-9. doi: 10.1016/0303-8467(80)90020-7.
The overall efficacy and tolerance of a new skeletal muscle relaxant DS 103-282 was evaluated by treating 10 patients with chronic spinal spasticity. Other agents such as baclofen, dantrolene sodium or diazepam had been only minimally beneficial in these patients. Treatment was started with DS 103-282 at a mean dosage of 7.4 mg. per day which was adjusted according to response up to 14.5 mg. per day at the end of the 8-week trial period. Objective rating assessments showed improvement in spasticity, medullary automatism and clonus. No changes were recorded in the reflex pattern nor improvement in disability scores. Only a few mild side-effects were reported, there was a noticeable absence of sedation, but reduction in systolic and diastolic blood pressure was noted in most patients. DS 103-282 appears to have demonstrable myotonolytic action and in view of its good tolerance it deserves further investigation.
通过对10例慢性脊髓痉挛患者进行治疗，评估了一种新型骨骼肌松弛剂DS 103-282的总体疗效和耐受性。巴氯芬、丹曲林钠或地西泮等其他药物对这些患者的疗效甚微。治疗从DS 103-282开始，平均每日剂量为7.4毫克，根据反应进行调整，在8周试验期结束时最高可达每日14.5毫克。客观评分评估显示痉挛、延髓自动症和阵挛有所改善。反射模式未记录到变化，残疾评分也未改善。仅报告了少数轻度副作用，明显没有镇静作用，但大多数患者的收缩压和舒张压有所降低。DS 103-282似乎具有明显的肌松作用，鉴于其良好的耐受性，值得进一步研究。
